Masimo Announces Expansion of Strategic Partnership with Philips

September 11, 2025 at 08:00 AM EDT

Multi-Year Partnership Renewal with Broadened Focus Will Include Expedited Technology Adoption and Market-Based Strategic Development of Next-Generation Monitoring Solutions

Masimo (NASDAQ: MASI) today announced a multi-year renewal and expansion of its strategic partnership with Royal Philips (NYSE: PHG, AEX: PHIA).

Building on over two decades of collaboration, this significant partnership expansion is designed to accelerate the integration of Masimo’s monitoring technologies, such as industry-leading SET^® pulse oximetry, into a variety of Philips multi-parameter patient monitors through 2026 and beyond. This includes integrating Masimo’s Radius PPG^® with Masimo-board equipped Philips monitors and next-generation wearable multi-parameter solutions, as well as integrating a range of Masimo sensor technology with all Masimo-equipped Philips bedside monitors and central stations. Philips and Masimo will also work together to strategically develop, produce, and co-promote next-generation artificial intelligence-based monitoring technologies, bringing the benefits of their mutual innovations in the coming years to millions more patients around the world.

In addition to clinically proven SET^® pulse oximetry, which is available on Philips patient monitors, numerous other Masimo monitoring technologies are already available on Philips devices, including advanced measurements such as continuous hemoglobin (SpHb^®), O3^® regional oximetry, SedLine^® brain function monitoring, and NomoLine^® capnography. As part of their renewed partnership, Philips is expediting adoption of these technologies in additional devices and market segments, increasing their availability to support more clinicians and patient care across the continuum of care.

“We are excited to continue to partner with Philips to bring Masimo’s newest innovations in wearables and artificial intelligence to Philips’ platforms,” said Katie Szyman, CEO of Masimo. “Expanding our strong, long-standing partnership with Philips allows us to build on our shared legacies of innovation and helps ensure that Masimo’s best-in-class technologies reach even more patients. Together, Masimo and Philips will continue to empower clinicians to transform patient care.”

“Our priority is helping clinicians deliver the best possible care to their patients, and that means staying ahead of the curve,” said Julia Strandberg, Executive Vice President and Business Leader Connected Care at Royal Philips. “This partnership allows us to respond quickly to evolving clinical needs and market trends, integrating proven technologies into solutions that are easy to use, reliable, and scalable.”

@Masimo | #Masimo

About Masimo

Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Our mission is to improve life, improve patient outcomes, reduce the cost of care, and take noninvasive monitoring to new sites and applications. Masimo SET^® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown to outperform other pulse oximetry technologies in over 100 independent and objective studies, which can be found at www.masimo.com/evidence/featured-studies/feature. Masimo SET^® is estimated to be used on more than 200 million patients around the world each year and is the primary pulse oximetry at all 10 top U.S. hospitals as ranked in the 2025 Newsweek World’s Best Hospitals listing. Additional information about Masimo and its products may be found at www.masimo.com.

Forward-Looking Statements - Masimo

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements other than statements of historical facts that address activities, events or developments that we expect, believe or anticipate will or may occur in the future. These forward-looking statements include, among others, statements regarding planned technology integrations and the impact of those integrations, future expansion of the availability and adoption of our technologies, the development of future patient monitoring solutions; and other matters that do not relate strictly to historical facts or statements of assumptions underlying any of the foregoing. These statements are often identified by the use of words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “on-going,” “opportunity,” “plan,” “potential,” “predicts,” “forecast,” “project,” “seek,” “should,” “will,” or “would,” the negative versions of these terms and similar expressions or variations, but the absence of such words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: our and our OEM partner’s ability to plan and execute technology integration projects in a timely manner, or at all; market adoption of our advanced monitoring technologies; and other factors discussed in the “Risk Factors” section of our most recent periodic reports filed with the Securities and Exchange Commission (“SEC”), including our most recent Form 10-K and Form 10-Q, all of which you may obtain for free on the SEC’s website at www.sec.gov. Forward-looking statements are not guarantees of future performance. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today’s date. We do not undertake any obligation to update, amend or clarify these statements or the “Risk Factors” contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250910359299/en/

Contacts

Investor Contact:

Eli Kammerman

(949) 297-7077

ekammerman@masimo.com

Media Contact:

Evan Lamb

949-396-3376

elamb@masimo.com

About Us

About Cabling Installation & Maintenance

Contact Cabling Installation & Maintenance

Editorial

Advertising and Sponsorship Sales

Subscriptions and Memberships

Feedback/Problems

Masimo Announces Expansion of Strategic Partnership with Philips

Contacts

More News